Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Interferon beta (IFN-beta) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-beta are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-beta may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-beta can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-beta in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis
Chen, Y., Kuchroo, V. K., Inobe, J.-I., Hafler, D. A., & Weiner, H. L. (1994) · Science · doi:10.1126/science.7520605 · Cited by 1,973
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Chemokines and the Arrest of Lymphocytes Rolling Under Flow Conditions
Campbell, J. J., Hedrick, J., Zlotnik, A., Siani, M. A., Thompson, D. A., & Butcher, E. C. (1998) · Science · doi:10.1126/science.279.5349.381 · Cited by 995
Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G., & Janeway, C. A. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.57 · Cited by 835
Epithelial cells as sensors for microbial infection.
Kagnoff, M. F., & Eckmann, L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119522 · Cited by 615
TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A. J., Old, L., & Bernard, C. C. A. (1998) · Nature Medicine · doi:10.1038/nm0198-078 · Cited by 550
Matrix metalloproteinases in immunity
Goetzl, E. J., Banda, M. J., & Leppert, D. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.1 · Cited by 544
Ransohoff, R. M., Hamilton, T. A., Tani, M., Stoler, M. H., Shick, H. E., Major, J. A., Estes, M. L., Thomas, D. M., & Tuohy, V. K. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.8472896 · Cited by 496
Cited by
Biclustering algorithms for biological data analysis: a survey
Madeira, S. C., & Oliveira, A. L. (2004) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2004.2 · Cited by 2,049
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
The measurement and clinical relevance of brain atrophy in multiple sclerosis
Bermel, R. A., & Bakshi, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70349-0 · Cited by 456
T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β
Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., & Novelli, F. (2009) · Annals of Neurology · doi:10.1002/ana.21652 · Cited by 375
Venken, K., Hellings, N., Thewissen, M., Somers, V., Hensen, K., Rummens, J., Medaer, R., Hupperts, R., & Stinissen, P. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02690.x · Cited by 360
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Disruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334
Keegan, B. M., & Noseworthy, J. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103909 · Cited by 319
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Multiple Sclerosis Is an Inflammatory T-Cell–Mediated Autoimmune Disease
Weiner, H. L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.10.1613 · Cited by 293
New natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia
Ejlerskov, P., Hultberg, J. G., Wang, J., Carlsson, R., Ambjørn, M., Kuss, M., Liu, Y., Porcu, G., Kolkova, K., Friis Rundsten, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.069 · Cited by 211
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Interferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Metadata
- Authors
- Wee Yong, V., Chabot, S., Stuve, O., & Williams, G.
- Venue
- Neurology
- Published
- 1998-09
- Volume
- 51
- Issue
- 3
- Pages
- 682-689
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2069947868
- Cited by
- 344
- References
- 38
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.